Properties of AgNPs stabilized with polyvinylpyrrolidone relevant to antidiabetic agents; Nanoscale; Vol. 18, iss. 2
| Parent link: | Nanoscale.— .— Cambridge: RSC Publishing Vol. 18, iss. 2.— 2026.— P. 918-931 |
|---|---|
| Andere auteurs: | , , , , , |
| Samenvatting: | Title screen Type 2 diabetes mellitus (DM2) is a chronic metabolic disease. Silver nanoparticles (AgNPs) show promise in their treatment. This study assessed the potential of AgNPs as DM2 treatment agent using in vitro, in vivo, and machine learning approaches. Male Wistar rats were used to study antihyperglycemic effects, while male mice evaluated hypoglycemic effects. In vivo studies showed that AgNPs inhibited α-amylase, α-glucosidase, and dipeptidyl peptidase-4, up to 3.51, 3827.76, and 11 times more effective than acarbose and sitagliptin, respectively. Advanced glycation end products inhibition by AgNPs was up to 61.4 times higher than metformin. In vivo experiments revealed that AgNPs antihyperglycemic activities were close to acarbose, while the same hypoglycemic effect was achieved with AgNP doses up to 167 times lower than that of glibenclamide. The results show the possibility to decrease the glibenclamide dose by two orders, that indicates high AgNP perspective to reduce drug toxicity and side effects Текстовый файл AM_Agreement |
| Taal: | Engels |
| Gepubliceerd in: |
2026
|
| Onderwerpen: | |
| Online toegang: | https://doi.org/10.1039/D5NR03452C |
| Formaat: | Elektronisch Hoofdstuk |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=684836 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 684836 | ||
| 005 | 20260213102822.0 | ||
| 090 | |a 684836 | ||
| 100 | |a 20260213d2026 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a GB | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Properties of AgNPs stabilized with polyvinylpyrrolidone relevant to antidiabetic agents |f V. V. Pineda, A. Alvarez de la Paz, N. Bogdanchikova [et al.] | |
| 203 | |a Текст |c электронный |b визуальный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 320 | |a References: 40 tit | ||
| 330 | |a Type 2 diabetes mellitus (DM2) is a chronic metabolic disease. Silver nanoparticles (AgNPs) show promise in their treatment. This study assessed the potential of AgNPs as DM2 treatment agent using in vitro, in vivo, and machine learning approaches. Male Wistar rats were used to study antihyperglycemic effects, while male mice evaluated hypoglycemic effects. In vivo studies showed that AgNPs inhibited α-amylase, α-glucosidase, and dipeptidyl peptidase-4, up to 3.51, 3827.76, and 11 times more effective than acarbose and sitagliptin, respectively. Advanced glycation end products inhibition by AgNPs was up to 61.4 times higher than metformin. In vivo experiments revealed that AgNPs antihyperglycemic activities were close to acarbose, while the same hypoglycemic effect was achieved with AgNP doses up to 167 times lower than that of glibenclamide. The results show the possibility to decrease the glibenclamide dose by two orders, that indicates high AgNP perspective to reduce drug toxicity and side effects | ||
| 336 | |a Текстовый файл | ||
| 371 | 0 | |a AM_Agreement | |
| 461 | 1 | |t Nanoscale |c Cambridge |n RSC Publishing | |
| 463 | 1 | |t Vol. 18, iss. 2 |v P. 918-931 |d 2026 | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 701 | |a Pineda |b V. V. |g Vera Victoria | ||
| 701 | |a Alvarez |b A. |g Antonio de la Paz | ||
| 701 | 1 | |a Bogdanchikova |b N. |g Nina | |
| 701 | 1 | |a Pestryakov |b A. N. |c Chemist |c Professor of Tomsk Polytechnic University, Doctor of Chemical Science |f 1963- |g Aleksey Nikolaevich |9 14796 | |
| 701 | 1 | |a Fernandez |b J. J. A. |g Juan Jose Acevedo | |
| 701 | 1 | |a Campos |b M. R. S. |g Maira Rubi Segura | |
| 801 | 0 | |a RU |b 63413507 |c 20260213 |g RCR | |
| 856 | 4 | 0 | |u https://doi.org/10.1039/D5NR03452C |z https://doi.org/10.1039/D5NR03452C |
| 942 | |c CF | ||